Terms: = Leukemia AND BUB1B, BUBR1, 701, ENSG00000156970, SSK1, BUB1beta, MAD3L, hBUBR1, Bub1A, O60566 AND Prognosis
20 results:
1. The Diagnostic and Prognostic Value of miR-155 in Cancers: An Updated Meta-analysis.
Wu Y; Hong Q; Lu F; Zhang Z; Li J; Nie Z; He B
Mol Diagn Ther; 2023 May; 27(3):283-301. PubMed ID: 36939982
[TBL] [Abstract] [Full Text] [Related]
2. Single-cell profiling of T cells uncovers a tissue-resident memory-like T-cell subset associated with bidirectional prognosis for B-cell acute lymphoblastic leukemia.
Lai W; Wang X; Liu L; Xu L; Mao L; Tan J; Zha X; Zhan H; Lei W; Lan Y; Chen G; Li Y; Luo OJ
Front Immunol; 2022; 13():957436. PubMed ID: 36532049
[TBL] [Abstract] [Full Text] [Related]
3. [Clinical features and prognosis of low triiodothyronine syndrome in patients with acute myeloid leukemia].
Li LZ; Hu JH; Xu ZY; Hong M; Sun Q; Qian SX; Liu WJ
Zhonghua Xue Ye Xue Za Zhi; 2021 Nov; 42(11):923-929. PubMed ID: 35045654
[No Abstract] [Full Text] [Related]
4. Expression and prognosis analyses of BUB1, bub1b and BUB3 in human sarcoma.
Long Z; Wu T; Tian Q; Carlson LA; Wang W; Wu G
Aging (Albany NY); 2021 Apr; 13(9):12395-12409. PubMed ID: 33872216
[TBL] [Abstract] [Full Text] [Related]
5. Association between the rs3751143 polymorphism of P2RX7 gene and chronic lymphocytic leukemia: A meta-analysis.
Zhang WJ; Zhu ZM
Purinergic Signal; 2020 Dec; 16(4):479-484. PubMed ID: 33026566
[TBL] [Abstract] [Full Text] [Related]
6. Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery.
Simonetti G; Padella A; do Valle IF; Fontana MC; Fonzi E; Bruno S; Baldazzi C; Guadagnuolo V; Manfrini M; Ferrari A; Paolini S; Papayannidis C; Marconi G; Franchini E; Zuffa E; Laginestra MA; Zanotti F; Astolfi A; Iacobucci I; Bernardi S; Sazzini M; Ficarra E; Hernandez JM; Vandenberghe P; Cools J; Bullinger L; Ottaviani E; Testoni N; Cavo M; Haferlach T; Castellani G; Remondini D; Martinelli G
Cancer; 2019 Mar; 125(5):712-725. PubMed ID: 30480765
[TBL] [Abstract] [Full Text] [Related]
7. RAS mutations in acute myeloid leukaemia patients: A review and meta-analysis.
Liu X; Ye Q; Zhao XP; Zhang PB; Li S; Li RQ; Zhao XL
Clin Chim Acta; 2019 Feb; 489():254-260. PubMed ID: 30194935
[TBL] [Abstract] [Full Text] [Related]
8. MDM4 overexpressed in acute myeloid leukemia patients with complex karyotype and wild-type TP53.
Li L; Tan Y; Chen X; Xu Z; Yang S; Ren F; Guo H; Wang X; Chen Y; Li G; Wang H
PLoS One; 2014; 9(11):e113088. PubMed ID: 25405759
[TBL] [Abstract] [Full Text] [Related]
9. New recurrent balanced translocations in acute myeloid leukemia and myelodysplastic syndromes: cancer and leukemia group B 8461.
Walker A; Mrózek K; Kohlschmidt J; Rao KW; Pettenati MJ; Sterling LJ; Marcucci G; Carroll AJ; Bloomfield CD;
Genes Chromosomes Cancer; 2013 Apr; 52(4):385-401. PubMed ID: 23225546
[TBL] [Abstract] [Full Text] [Related]
10. Clinicopathological significance and prognostic value of leukemia-related protein 16 expression in invasive ductal breast carcinoma.
Zhao P; Lu Y; Han W
Cancer Sci; 2010 Oct; 101(10):2262-8. PubMed ID: 20649898
[TBL] [Abstract] [Full Text] [Related]
11. Lestaurtinib, a multitargeted tyrosine kinase inhibitor: from bench to bedside.
Shabbir M; Stuart R
Expert Opin Investig Drugs; 2010 Mar; 19(3):427-36. PubMed ID: 20141349
[TBL] [Abstract] [Full Text] [Related]
12. Effect of FLT3 inhibition on normal hematopoietic progenitor cells.
Weisel KC; Yildirim S; Schweikle E; Kanz L; Möhle R
Ann N Y Acad Sci; 2007 Jun; 1106():190-6. PubMed ID: 17442779
[TBL] [Abstract] [Full Text] [Related]
13. Constitutively activated FLT3 phosphorylates BAD partially through pim-1.
Kim KT; Levis M; Small D
Br J Haematol; 2006 Sep; 134(5):500-9. PubMed ID: 16869825
[TBL] [Abstract] [Full Text] [Related]
14. Combinations of the FLT3 inhibitor CEP-701 and chemotherapy synergistically kill infant and childhood MLL-rearranged ALL cells in a sequence-dependent manner.
Brown P; Levis M; McIntyre E; Griesemer M; Small D
Leukemia; 2006 Aug; 20(8):1368-76. PubMed ID: 16761017
[TBL] [Abstract] [Full Text] [Related]
15. Apoptosis and immaturity in acute myeloid leukemia.
Del Principe MI; Del Poeta G; Venditti A; Buccisano F; Maurillo L; Mazzone C; Bruno A; Neri B; Irno Consalvo M; Lo Coco F; Amadori S
Hematology; 2005 Feb; 10(1):25-34. PubMed ID: 16019442
[TBL] [Abstract] [Full Text] [Related]
16. Flt3 receptor tyrosine kinase as a drug target in leukemia.
Schmidt-Arras D; Schwäble J; Böhmer FD; Serve H
Curr Pharm Des; 2004; 10(16):1867-83. PubMed ID: 15180525
[TBL] [Abstract] [Full Text] [Related]
17. Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition.
Brown P; Meshinchi S; Levis M; Alonzo TA; Gerbing R; Lange B; Arceci R; Small D
Blood; 2004 Sep; 104(6):1841-9. PubMed ID: 15166029
[TBL] [Abstract] [Full Text] [Related]
18. Internal tandem duplication mutation of FLT3 blocks myeloid differentiation through suppression of C/EBPalpha expression.
Zheng R; Friedman AD; Levis M; Li L; Weir EG; Small D
Blood; 2004 Mar; 103(5):1883-90. PubMed ID: 14592841
[TBL] [Abstract] [Full Text] [Related]
19. Targeted inhibition of FLT3 overcomes the block to myeloid differentiation in 32Dcl3 cells caused by expression of FLT3/ITD mutations.
Zheng R; Friedman AD; Small D
Blood; 2002 Dec; 100(12):4154-61. PubMed ID: 12393674
[TBL] [Abstract] [Full Text] [Related]
20. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo.
Levis M; Allebach J; Tse KF; Zheng R; Baldwin BR; Smith BD; Jones-Bolin S; Ruggeri B; Dionne C; Small D
Blood; 2002 Jun; 99(11):3885-91. PubMed ID: 12010785
[TBL] [Abstract] [Full Text] [Related]
